Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...
Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.
In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report). The ...
MedPage Today celebrated its 20th anniversary on March 15. To get a sense of its early days -- and the new ground it was ...
Globus Medical, Inc. reported $657,293 million in sales and $60,275 million in operating profit for the quarter ending December 31, 2024, which was above both Wall Street’s expectations and management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results